• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GNFT

    GENFIT S.A.

    Subscribe to $GNFT
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: genfit.com

    Peers

    $CNCE
    $GALT
    $ICPT
    $IVA

    Recent Analyst Ratings for GENFIT S.A.

    DatePrice TargetRatingAnalyst
    8/19/2025$9.00Buy
    H.C. Wainwright
    12/20/2021$8.00Neutral → Buy
    HC Wainwright & Co.
    9/30/2021$8.00 → $7.00Neutral
    HC Wainwright & Co.
    See more ratings

    GENFIT S.A. SEC Filings

    View All

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    7/8/25 4:10:11 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    6/17/25 2:50:04 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/22/25 4:10:12 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/20/25 4:10:43 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/14/25 4:10:56 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/7/25 4:10:07 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/5/25 6:00:48 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    4/29/25 3:10:19 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 20-F filed by GENFIT S.A.

    20-F - Genfit S.A. (0001757064) (Filer)

    4/29/25 2:52:02 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    4/28/25 4:10:57 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENFIT S.A. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Genfit with a new price target

    H.C. Wainwright resumed coverage of Genfit with a rating of Buy and set a new price target of $9.00

    8/19/25 8:33:55 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genfit upgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00

    12/20/21 6:28:59 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on Genfit with a new price target

    HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously

    9/30/21 6:11:01 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVB Leerink reiterated coverage on Genfit with a new price target

    SVB Leerink reiterated coverage of Genfit with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

    4/5/21 6:31:27 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genfit upgraded by Bryan, Garnier & Co

    Bryan, Garnier & Co upgraded Genfit from Neutral to Buy

    2/12/21 9:03:51 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENFIT S.A. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

    Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic

    5/31/23 4:44:00 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

    Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

    12/17/21 1:00:00 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENFIT S.A. Financials

    Live finance-specific insights

    View All

    Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

    Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

    12/17/21 1:00:00 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENFIT S.A. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

    SC 13G/A - Genfit S.A. (0001757064) (Subject)

    2/14/24 4:00:25 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by GENFIT S.A.

    SC 13G - Genfit S.A. (0001757064) (Subject)

    5/1/23 4:00:10 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

    SC 13G/A - Genfit S.A. (0001757064) (Subject)

    2/14/22 6:28:17 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - Genfit S.A. (0001757064) (Subject)

    2/22/21 4:01:11 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care